One of the largest Phase III trials ever conducted in pancreatic cancer has shown that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs su 6 June 2016
A Phase III trial of Johnson and Johnson (NYSE: JNJ) subsidiary Janssen’s Darzalex (daratumumab) in combination with Velcade (bortezomib) and dexamethasone (Dvd 5 June 2016
A precision medicine approach using a patient’s individual tumor biomarkers to determine the best treatment leads to significantly better outcomes, according to 4 June 2016
German cancer specialist CellAct Pharma has presented positive new data on CAP7.1 for the treatment of biliary tract cancers at the Annual Meeting of the Americ 3 June 2016
German family-owned pharma major Boehringer Ingelheim has launched a trial to further investigate olmutinib (BI 1482694) as a treatment for epidermal growth fac 3 June 2016
Patients with metastatic colorectal cancer are more likely to survive if their tumor originates on the left-side of the colon versus the right, a study has reve 19 May 2016
Merck & Co’s Keytruda improves long-term survival rates in newly diagnosed and previously treated patients with advanced melanoma, according to the results of a 18 May 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.